Advanced Cancer
Conditions
Brief summary
The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in participants with solid cancers that are advanced or have spread.
Interventions
DRUGBMS-986178
Specified dose on specified days
DRUGNivolumab
Specified dose on specified days
DRUGIpilimumab
Specified dose on specified days
BIOLOGICALTetanus vaccine
Specified dose on specified days
BIOLOGICALDPV-001 vaccine
DPV-001 (UbiLT3 and UbiLT6): Specified dose on specified days
DRUGCyclophosphamide
Specified dose on specified days
Sponsors
Bristol-Myers Squibb
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: For Part 9 (only arm open for enrollment): * Stage IV metastatic or unresectable triple negative breast cancer (TNBC) with zero or one prior systemic therapies in the advanced metastatic setting * Participants with \< 12 months from receipt of last curative-intent chemotherapy are allowed; curative chemotherapy will be considered first-line therapy * Prior receipt of chemotherapy in the (neo)adjuvant setting is acceptable, as long as completed greater than 6 months from start of treatment * Tumor biopsy samples (mandatory pre- and on-treatment biopsies) are required for all participants enrolled * Must have histologic or cytologic confirmation of a malignancy that is advanced (metastatic, recurrent, refractory, and/or unresectable) with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 * Men and women must agree to follow specific methods of contraception, if applicable
Exclusion criteria
* Must be immunotherapy treatment naïve, including no prior therapy with T cell immune checkpoint blocker (anti-PDL1, anti-PD1). Prior receipt of intralymphatic cytokine therapy (IRX-2) is acceptable (Part 9 only) * Other active malignancy requiring concurrent intervention * Prior therapy with any agent specifically targeting T-cell co-stimulation pathways such as anti-OX40 antibody, anti-CD137, anti- glucocorticoid-induced TNFR-related gene (anti-GITR) antibody, and anti-CD27 * Known or underlying medical or psychiatric condition and/or social reason that, in the opinion of the investigator or Sponsor, could make the administration of study drug hazardous to the participant or could adversely affect the ability of the participant to comply with or tolerate the study Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | From first dose to 28 days after first dose | The number of participants experiencing dose-limiting toxicities (DLTs) to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. DLTs are defined based on the incidence, severity, and duration of adverse events (AEs) for which no clear alternative cause is identified. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. |
| The Number of Participants Experiencing Adverse Events (AEs) | From first dose to 100 days after last dose (up to approximately 2.5 years) | The number of participants experiencing adverse events (AEs) to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. |
| The Number of Participants Experiencing Serious Adverse Events (SAEs) | From first dose to 100 days after last dose (up to approximately 2.5 years) | The number of participants experiencing serious adverse events (SAEs) to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. A SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or is an important medical event. |
| The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | From first dose to 100 days after last dose (up to approximately 2.5 years) | The number of participants experiencing adverse events (AEs) leading to discontinuation of study drug to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. |
| The Number of Participant Deaths | From first dose to study completion (up to approximately 4 years 5 months) | The number of deaths in each arm to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. |
| The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | From baseline to 100 days after last dose (up to approximately 2.5 years) | The number of participants with clinical laboratory test abnormalities to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. Results will be categorized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life Threatening Grade 5 = Death Related to AE Baseline is defined as the last non-missing measurement prior to the first dosing date and time |
| The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | From baseline to 100 days after last dose (up to approximately 2.5 years) | The number of participants with clinical laboratory test abnormalities to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. Results will be categorized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life Threatening Grade 5 = Death Related to AE Baseline is defined as the last non-missing measurement prior to the first dosing date and time |
| The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | From baseline to 100 days after last dose (up to approximately 2.5 years) | The number of participants with clinical laboratory test abnormalities to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. Results will be categorized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life Threatening Grade 5 = Death Related to AE Baseline is defined as the last non-missing measurement prior to the first dosing date and time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CLT: Total Body Clearance | Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) | The total body clearance was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead. |
| Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) | Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) | The average concentration over a dosing interval (AUC(TAU)/tau) was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead. |
| AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) | The ratio of an exposure measure at steady state to that after the first dose was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead. |
| AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC) | Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) | The ratio of an exposure measure at steady state to that after the first dose was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead. |
| AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau) | Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) | The ratio of an exposure measure at steady state to that after the first dose was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead. |
| T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) | Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) | The effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab |
| Objective Response Rate (ORR) | From baseline up to approximately 2.5 years | The total number of participants whose best overall response (BOR) is either a complete response (CR) or partial response (PR) based on assessment of tumor response using RECIST v1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions. Overall Response (OR) = CR + PR Baseline is defined as the last non-missing measurement prior to the first dosing date and time. |
| Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | Cycle 1-6 timepoints can include (Pre-dose, 696 hours post dose) | The number of participants with positive anti-drug antibodies (ADA) is assessed to characterize the immunogenicity of BMS-986178 administered alone or in combination with nivolumab and/or ipilimumab. ADA Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment. |
| Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab | Cycle 1-6 timepoints can include (Pre-dose, 336, 696 hours post dose) | The number of participants with positive anti-drug antibodies (ADA) is assessed to characterize the immunogenicity of Nivolumab administered with BMS-986178 ADA Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment. |
| Frequency of Positive Anti-Drug Antibodies (ADA) to Ipilimumab. | Cycle 1-6 timepoints can include (Pre-dose, 696 hours post dose) | The number of participants with positive anti-drug antibodies (ADA) is assessed to characterize the immunogenicity of Ipilimumab administered with BMS-986178 ADA Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment. |
| The Number of Participants Showing a Change in Soluble OX40 and Peripheral OX40 Receptor Occupancy Pharmacodynamic Biomarkers in Part 8 | Cycle 1-6 timepoints can include (Pre-dose, 24, 168, 336, 672, 1848 hours post dose) | The Number of Participants Showing a Change in Soluble OX40 and Peripheral OX40 Receptor Occupancy Pharmacodynamic Biomarkers in Part 8. A threshold of 80% receptor occupancy following treatment was applied. |
| Tumor Pharmacodynamics of BMS-986178 in Combination With Nivolumab or Nivolumab Monotherapy in Part 8 | Screening, cycle 1-2 timepoints can include (Pre-dose, 336, 1848 hours post dose) | Tumor pharmacodynamics of BMS-986178 in combination with nivolumab or nivolumab monotherapy |
| The Number of Participants With Sustained T Cell Expansion With DPV-001 in Combination With Nivolumab or Nivolumab Monotherapy in Part 9 | Cycle 1-6 timepoints can include (Pre-dose, 24, 168, 336, 672, 1848 hours post dose) | The number of participants with Sustained T Cell Expansion with DPV-001 in Combination with Nivolumab or Nivolumab Monotherapy was assessed to show a change in pharmacodynamics biomarkers |
| Ctrough: Trough Observed Plasma Concentration | Cycle 1-17 timepoints can include (Pre-dose, 336, 504, 672 hours post dose) | Trough observed plasma concentration (this includes predose concentrations and Ctau concentrations) was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead. |
| Duration of Response (DOR) | From baseline up to approximately 2.5 years | The time between the date of first response and the subsequent date of disease progression or death (death after re-treatment will not be considered), whichever occurs first in participants with a best overall response (BOR) of complete response (CR) or partial response (PR). Best overall response (BOR) is assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions. Baseline is defined as the last non-missing measurement prior to the first dosing date and time. Due to high percentage of censored response, median estimate may be misleading |
| Progression Free Survival (PFS) Rate at 24 Weeks | 24 weeks after first dose | The percentage of treated participants remaining progression free and surviving at 24 weeks since the first dosing date. |
| Cmax: Maximum Observed Serum Concentration | Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) | The maximum observed serum concentration was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead. |
| Tmax: Time of Maximum Observed Serum Concentration | Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) | The time of maximum observed serum concentration was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab |
| AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) | The area under the serum concentration-time curve from time 0 to time t was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead. |
| AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) | The area under the serum concentration-time curve in 1 dosing interval was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead. |
| Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) | The observed serum concentration at the end of a dosing interval when intensive samples are collected was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead. |
Countries
Canada, Israel, Italy, Netherlands, Spain, United States
Participant flow
Pre-assignment details
165 participants were randomized and treated in Parts 1-8. 1 Participant was randomized and treated in Part 9 Cohort 1. Parts 2B, 2D, 2E, 3B, 3C, and Part 9 Cohort 2 did not enroll any participants.
Participants by arm
| Arm | Count |
|---|---|
| Escalation Part 1: BMS 20 mg Q2W Part 1A is BMS-986178 monotherapy dose escalation. Dosing of BMS-986178 20mg will begin on Day 1 of each cycle and will be administered every 2 week (q2w) for up to 12 cycles. | 4 |
| Escalation Part 1: BMS 40 mg Q2W Part 1A is BMS-986178 monotherapy dose escalation. Dosing of BMS-986178 40mg will begin on Day 1 of each cycle and will be administered every 2 week (q2w) for up to 12 cycles. | 4 |
| Escalation Part 1: BMS 80 mg Q2W Part 1A is BMS-986178 monotherapy dose escalation. Dosing of BMS-986178 80mg will begin on Day 1 of each cycle and will be administered every 2 week (q2w) for up to 12 cycles. | 4 |
| Escalation Part 1: BMS 160 mg Q2W Part 1A is BMS-986178 monotherapy dose escalation. Dosing of BMS-986178 160mg will begin on Day 1 of each cycle and will be administered every 2 week (q2w) for up to 12 cycles. | 4 |
| Escalation Part 1: BMS 320 mg Q2W Part 1A is BMS-986178 monotherapy dose escalation. Dosing of BMS-986178 320mg will begin on Day 1 of each cycle and will be administered every 2 week (q2w) for up to 12 cycles. | 4 |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W Dosing of BMS-986178 20mg and Nivolumab flat dose of 240 mg will be administered every 2 weeks (q2w) starting on Day 1 of each cycle for up to 12 cycles. | 7 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W Dosing of BMS-986178 40mg and Nivolumab flat dose of 240 mg will be administered every 2 weeks (q2w) starting on Day 1 of each cycle for up to 12 cycles. | 8 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W Dosing of BMS-986178 80mg and Nivolumab flat dose of 240 mg will be administered every 2 weeks (q2w) starting on Day 1 of each cycle for up to 12 cycles. | 12 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W Dosing of BMS-986178 160mg and Nivolumab flat dose of 240 mg will be administered every 2 weeks (q2w) starting on Day 1 of each cycle for up to 12 cycles. | 8 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W Dosing of BMS-986178 320mg and Nivolumab flat dose of 240 mg will be administered every 2 weeks (q2w) starting on Day 1 of each cycle for up to 12 cycles. | 8 |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W Each treatment cycle will be 3 weeks in length. BMS-986178 20mg will be administered q3w starting on Cycle 1 Day 1, up to and including 8 cycles. Ipilimumab will be administered at a dose of 1 mg/kg q3w starting on Day 1 for 4 cycles. Only BMS-986178 will be administered in the last 4 cycles. | 4 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W Each treatment cycle will be 3 weeks in length. BMS-986178 40mg will be administered q3w starting on Cycle 1 Day 1, up to and including 8 cycles. Ipilimumab will be administered at a dose of 1 mg/kg q3w starting on Day 1 for 4 cycles. Only BMS-986178 will be administered in the last 4 cycles. | 10 |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W Each treatment cycle will be 3 weeks in length. BMS-986178 80mg will be administered q3w starting on Cycle 1 Day 1, up to and including 8 cycles. Ipilimumab will be administered at a dose of 1 mg/kg q3w starting on Day 1 for 4 cycles. Only BMS-986178 will be administered in the last 4 cycles. | 7 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W Each treatment cycle will be 3 weeks in length. BMS-986178 160mg will be administered q3w starting on Cycle 1 Day 1, up to and including 8 cycles. Ipilimumab will be administered at a dose of 1 mg/kg q3w starting on Day 1 for 4 cycles. Only BMS-986178 will be administered in the last 4 cycles. | 8 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W Each treatment cycle will be 3 weeks in length. BMS-986178 320mg will be administered q3w starting on Cycle 1 Day 1, up to and including 8 cycles. Ipilimumab will be administered at a dose of 1 mg/kg q3w starting on Day 1 for 4 cycles. Only BMS-986178 will be administered in the last 4 cycles. | 6 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) Participants with bladder cancer receive BMS-986178 (80 mg) and Nivolumab administered at a flat dose of 240 mg. Each treatment cycle will be 2 weeks in length and study drugs will be administered every 2 weeks starting on Day 1 of each cycle for up to 12 cycles. | 18 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W Combination arm of BMS-986178 (80 mg) with nivolumab (480 mg) to be administered every 4 weeks (q4w). | 12 |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W Combination arm of BMS-986178 (80 mg) with Ipilimumab 3 mg/kg administered every 3 weeks (q3w) for 4 doses, followed by monotherapy with BMS-986178 (maintenance therapy). | 6 |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) Participants with renal cell carcinoma (RCC) recieve BMS-986178 (40mg) administered at a flat dose in combination with nivolumab (240 mg) and ipilimumab (1 mg/kg) every 3 weeks (q3w) during Cycles 1 to 4, followed by maintenance therapy (Cycle 5 and beyond) in which BMS-986178 (40 mg) and nivolumab (480 mg) will be administered every 4 weeks (q4w). Study drugs will be administered accordingly starting on Day 1 of each cycle. | 7 |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) Participants with renal cell carcinoma (RCC) receive BMS-986178 (40mg) administered combination with nivolumab (240 mg) and ipilimumab (1 mg/kg) every 3 weeks (q3w) during Cycles 1 to 4 followed by maintenance therapy (Cycle 5 and beyond) in which BMS-986178 and nivolumab (480 mg) will be administered every 4 weeks (q4w). Study drugs will be administered accordingly starting on Day 1 of each cycle. | 1 |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) BMS-986178 will be administered at a flat dose of 40 mg (q2w) in combination with nivolumab (240 mg; q2w) and ipilimumab (1 mg/kg; q6w) for four 6-week cycles. Study drugs will be administered accordingly starting on Day 1 of each cycle. If participants continue for additional cycles, past cycle 4, all study drugs (BMS-986178/nivolumab/ipilimumab) will continue for all cycles. | 6 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) Participants with non-small cell lung cancer (NSCLC) receive BMS-986178 (40 mg) in combination with nivolumab 240 mg every 2 weeks (q2w) and ipilimumab 1 mg/kg every 6 weeks (q6w) for four, 6-week cycles. Study drugs will be administered accordingly starting on Day 1 of each cycle. | 9 |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W BMS-986178 (20 mg) will be administered as a flat dose every 12 weeks (q12w) in combination with nivolumab flat dose (480 mg) every 4 weeks (q4w). Each treatment cycle will be 12 weeks in length starting on Day 1 of each cycle. There will be up to 9 cycles, to allow for 24 months of treatment. A tetanus vaccine (Tdap preferred, Td or equivalent after discussion with the medical monitor) will be administered first on Cycle 1 Day 1 prior to administration of nivolumab and BMS-986178. | 2 |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W BMS-986178 (40 mg) will be administered as a flat dose every 12 weeks (q12w) in combination with nivolumab flat dose (480 mg) every 4 weeks (q4w). Each treatment cycle will be 12 weeks in length starting on Day 1 of each cycle. There will be up to 9 cycles, to allow for 24 months of treatment. A tetanus vaccine (Tdap preferred, Td or equivalent after discussion with the medical monitor) will be administered first on Cycle 1 Day 1 prior to administration of nivolumab and BMS-986178. | 2 |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W BMS-986178 (80 mg) will be administered as a flat dose every 12 weeks (q12w) in combination with nivolumab flat dose (480 mg) every 4 weeks (q4w). Each treatment cycle will be 12 weeks in length starting on Day 1 of each cycle. There will be up to 9 cycles, to allow for 24 months of treatment. A tetanus vaccine (Tdap preferred, Td or equivalent after discussion with the medical monitor) will be administered first on Cycle 1 Day 1 prior to administration of nivolumab and BMS-986178. | 2 |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W Nivolumab monotherapy will be administered as a flat dose of 480 mg every 4 weeks (q4w). Each treatment cycle will be 12 weeks in length and will be dosed for up to 9 cycles, 24 months of dosing. Treatment will be given on Day 1, Day 29 and 57 of each cycle. . A tetanus vaccine (Tdap preferred, Td or equivalent after discussion with the medical monitor) will be administered first on Cycle 1 Day 1 prior to administration of nivolumab monotherapy. | 2 |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine Cohort 1: Cyclophosphamide 300 mg/m2 was administered 3 days prior to C1D1. DPV-001 1 mg was given on C1D1 intranodal then intradermal on C1D8, C1D15, C2D1, C2D15, C3D1, C4D1, C5D1, C6D1, C9D1 and C12D1. Nivolumab 240 mg was administered on C1D15 followed by nivolumab 480 mg was Q4W on day 1 of cycles 2-26. BMS-986178 40 mg infusion was administered on day 1 of cycles 1-6, 9, and 12. Each treatment cycle is 4 weeks and there are up to 26 cycles. | 1 |
| Total | 166 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 | FG012 | FG013 | FG014 | FG015 | FG016 | FG017 | FG018 | FG019 | FG020 | FG021 | FG022 | FG023 | FG024 | FG025 | FG026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Death | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 4 | 2 | 2 | 0 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Disease Progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Overall Study | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Other reasons | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 |
| Overall Study | Participant withdrew consent | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Total | Escalation Part 1: BMS 40 mg Q2W | Escalation Part 1: BMS 80 mg Q2W | Escalation Part 1: BMS 160 mg Q2W | Escalation Part 1: BMS 320 mg Q2W | Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Escalation Part 1: BMS 20 mg Q2W | Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 66 Participants | 3 Participants | 2 Participants | 3 Participants | 1 Participants | 2 Participants | 5 Participants | 0 Participants | 2 Participants | 3 Participants | 3 Participants | 1 Participants | 3 Participants | 3 Participants | 1 Participants | 2 Participants | 10 Participants | 4 Participants | 1 Participants | 0 Participants | 1 Participants | 4 Participants | 7 Participants | 0 Participants | 1 Participants | 2 Participants | 2 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 100 Participants | 1 Participants | 2 Participants | 1 Participants | 3 Participants | 5 Participants | 3 Participants | 4 Participants | 10 Participants | 5 Participants | 5 Participants | 3 Participants | 7 Participants | 4 Participants | 7 Participants | 4 Participants | 8 Participants | 8 Participants | 5 Participants | 7 Participants | 0 Participants | 2 Participants | 2 Participants | 2 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 6 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 89 Participants | 4 Participants | 4 Participants | 3 Participants | 2 Participants | 6 Participants | 6 Participants | 3 Participants | 5 Participants | 3 Participants | 3 Participants | 2 Participants | 7 Participants | 4 Participants | 4 Participants | 5 Participants | 6 Participants | 5 Participants | 3 Participants | 0 Participants | 1 Participants | 4 Participants | 3 Participants | 1 Participants | 2 Participants | 1 Participants | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 71 Participants | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 0 Participants | 2 Participants | 0 Participants | 6 Participants | 5 Participants | 5 Participants | 2 Participants | 3 Participants | 1 Participants | 4 Participants | 1 Participants | 12 Participants | 7 Participants | 3 Participants | 6 Participants | 0 Participants | 2 Participants | 6 Participants | 1 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 4 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 155 Participants | 3 Participants | 4 Participants | 4 Participants | 3 Participants | 6 Participants | 8 Participants | 2 Participants | 12 Participants | 8 Participants | 8 Participants | 4 Participants | 8 Participants | 7 Participants | 7 Participants | 6 Participants | 18 Participants | 11 Participants | 6 Participants | 7 Participants | 1 Participants | 5 Participants | 8 Participants | 2 Participants | 2 Participants | 2 Participants | 2 Participants | 1 Participants |
| Sex: Female, Male Female | 67 Participants | 1 Participants | 3 Participants | 1 Participants | 1 Participants | 3 Participants | 6 Participants | 1 Participants | 3 Participants | 6 Participants | 2 Participants | 3 Participants | 5 Participants | 4 Participants | 7 Participants | 2 Participants | 1 Participants | 8 Participants | 3 Participants | 2 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants |
| Sex: Female, Male Male | 99 Participants | 3 Participants | 1 Participants | 3 Participants | 3 Participants | 4 Participants | 2 Participants | 3 Participants | 9 Participants | 2 Participants | 6 Participants | 1 Participants | 5 Participants | 3 Participants | 1 Participants | 4 Participants | 17 Participants | 4 Participants | 3 Participants | 5 Participants | 1 Participants | 4 Participants | 9 Participants | 2 Participants | 1 Participants | 1 Participants | 2 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk | EG013 affected / at risk | EG014 affected / at risk | EG015 affected / at risk | EG016 affected / at risk | EG017 affected / at risk | EG018 affected / at risk | EG019 affected / at risk | EG020 affected / at risk | EG021 affected / at risk | EG022 affected / at risk | EG023 affected / at risk | EG024 affected / at risk | EG025 affected / at risk | EG026 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 4 / 4 | 4 / 4 | 3 / 4 | 4 / 4 | 4 / 4 | 3 / 7 | 7 / 8 | 11 / 12 | 6 / 8 | 6 / 8 | 4 / 4 | 9 / 10 | 7 / 7 | 8 / 8 | 2 / 6 | 16 / 18 | 11 / 12 | 3 / 6 | 3 / 7 | 0 / 1 | 5 / 6 | 4 / 9 | 2 / 2 | 2 / 2 | 1 / 2 | 1 / 2 | 1 / 1 |
| other Total, other adverse events | 4 / 4 | 4 / 4 | 4 / 4 | 3 / 4 | 4 / 4 | 7 / 7 | 8 / 8 | 12 / 12 | 6 / 8 | 8 / 8 | 4 / 4 | 10 / 10 | 7 / 7 | 8 / 8 | 6 / 6 | 18 / 18 | 11 / 12 | 6 / 6 | 5 / 7 | 1 / 1 | 6 / 6 | 9 / 9 | 2 / 2 | 2 / 2 | 2 / 2 | 2 / 2 | 1 / 1 |
| serious Total, serious adverse events | 3 / 4 | 4 / 4 | 2 / 4 | 3 / 4 | 3 / 4 | 3 / 7 | 6 / 8 | 7 / 12 | 4 / 8 | 5 / 8 | 2 / 4 | 6 / 10 | 6 / 7 | 5 / 8 | 2 / 6 | 11 / 18 | 7 / 12 | 4 / 6 | 4 / 7 | 1 / 1 | 6 / 6 | 5 / 9 | 0 / 2 | 1 / 2 | 1 / 2 | 1 / 2 | 1 / 1 |
Outcome results
Primary
The Number of Participant Deaths
The number of deaths in each arm to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors.
Time frame: From first dose to study completion (up to approximately 4 years 5 months)
Population: All treated participants (Parts 1-9)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participant Deaths | 4 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participant Deaths | 4 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participant Deaths | 3 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participant Deaths | 4 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participant Deaths | 4 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participant Deaths | 3 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participant Deaths | 7 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participant Deaths | 11 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participant Deaths | 6 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participant Deaths | 6 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participant Deaths | 4 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participant Deaths | 9 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participant Deaths | 7 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participant Deaths | 8 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participant Deaths | 2 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participant Deaths | 16 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participant Deaths | 11 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participant Deaths | 3 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participant Deaths | 3 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participant Deaths | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participant Deaths | 5 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participant Deaths | 4 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participant Deaths | 2 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participant Deaths | 2 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participant Deaths | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participant Deaths | 1 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participant Deaths | 1 Participants |
Primary
The Number of Participants Experiencing Adverse Events (AEs)
The number of participants experiencing adverse events (AEs) to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 100 days after last dose (up to approximately 2.5 years)
Population: All treated participants (Parts 1-9)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) | 4 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) | 4 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) | 4 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) | 3 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) | 4 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) | 7 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) | 8 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) | 12 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) | 7 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) | 8 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Adverse Events (AEs) | 4 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Adverse Events (AEs) | 10 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Adverse Events (AEs) | 7 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Adverse Events (AEs) | 8 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Adverse Events (AEs) | 6 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants Experiencing Adverse Events (AEs) | 18 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants Experiencing Adverse Events (AEs) | 12 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants Experiencing Adverse Events (AEs) | 6 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants Experiencing Adverse Events (AEs) | 6 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants Experiencing Adverse Events (AEs) | 1 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants Experiencing Adverse Events (AEs) | 6 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants Experiencing Adverse Events (AEs) | 9 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants Experiencing Adverse Events (AEs) | 2 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants Experiencing Adverse Events (AEs) | 2 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants Experiencing Adverse Events (AEs) | 2 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants Experiencing Adverse Events (AEs) | 2 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants Experiencing Adverse Events (AEs) | 1 Participants |
Primary
The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
The number of participants experiencing adverse events (AEs) leading to discontinuation of study drug to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 100 days after last dose (up to approximately 2.5 years)
Population: All treated participants (Parts 1-9)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 1 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 2 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 2 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 2 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 2 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 0 Participants |
Primary
The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
The number of participants experiencing dose-limiting toxicities (DLTs) to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. DLTs are defined based on the incidence, severity, and duration of adverse events (AEs) for which no clear alternative cause is identified. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 28 days after first dose
Population: All treated participants (Parts 1-9)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 1 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 1 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 Participants |
Primary
The Number of Participants Experiencing Serious Adverse Events (SAEs)
The number of participants experiencing serious adverse events (SAEs) to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. A SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or is an important medical event.
Time frame: From first dose to 100 days after last dose (up to approximately 2.5 years)
Population: All treated participants (Parts 1-9)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 3 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 4 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 2 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 3 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 3 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 3 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 6 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 7 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 4 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 5 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 2 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 6 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 6 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 5 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 2 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 11 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 7 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 4 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 4 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 1 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 6 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 5 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 1 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants Experiencing Serious Adverse Events (SAEs) | 1 Participants |
Primary
The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology)
The number of participants with clinical laboratory test abnormalities to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. Results will be categorized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life Threatening Grade 5 = Death Related to AE Baseline is defined as the last non-missing measurement prior to the first dosing date and time
Time frame: From baseline to 100 days after last dose (up to approximately 2.5 years)
Population: All treated participants with on-treatment laboratory results and CTC grade criteria available (Parts 1-9)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 2 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 4 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 2 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 1 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 1 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 1 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 1 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 1 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 1 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 4 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 4 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 2 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 2 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 2 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 3 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 5 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 3 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 3 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 2 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 2 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 1 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 2 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 2 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 6 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 3 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 6 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 4 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 3 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 5 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 2 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 3 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 4 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 1 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 1 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 1 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 2 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 4 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 6 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 3 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 9 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 2 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 1 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 4 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 1 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 1 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 5 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 3 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 2 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 2 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 3 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 2 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 1 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 1 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 2 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 2 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 1 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 1 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 1 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 2 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 2 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 1 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 2 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 1 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 7 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 1 | 1 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 1 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 2 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 2 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 1 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 4 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 2 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | HEMOGLOBIN GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | ABSOLUTE NEUTROPHIL COUNT DRV. GRADE 4 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | PLATELET COUNT GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 2 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) | LEUKOCYTES GRADE 1 | 0 Participants |
Primary
The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION)
The number of participants with clinical laboratory test abnormalities to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. Results will be categorized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life Threatening Grade 5 = Death Related to AE Baseline is defined as the last non-missing measurement prior to the first dosing date and time
Time frame: From baseline to 100 days after last dose (up to approximately 2.5 years)
Population: All treated participants with on-treatment laboratory results and CTC grade criteria available (Parts 1-9)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 3 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 3 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 2 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 2 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 3 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 1 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 5 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 2 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 3 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 2 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 4 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 4 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 2 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 2 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 3 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 2 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 2 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 5 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 6 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 6 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 1 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 2 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 4 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 2 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 1 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 2 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 2 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 3 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 4 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 4 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 1 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 3 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 4 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 3 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 1 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 2 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 1 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 3 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 7 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 2 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 3 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 2 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 7 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 2 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 10 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 7 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 5 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 2 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 4 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 6 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 1 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 1 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 1 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 4 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 2 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 3 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 1 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 2 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 3 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 1 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 1 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 1 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 1 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 1 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 1 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 3 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 3 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 1 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 2 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 5 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 2 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 2 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 3 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 2 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 2 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 3 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 2 | 1 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 2 | 1 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 1 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 1 | 1 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 1 | 1 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALKALINE PHOSPHATASE GRADE 2 | 1 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 2 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ALANINE AMINOTRANSFERASE GRADE 1 | 1 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | ASPARTATE AMINOTRANSFERASE GRADE 4 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 1 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | BILIRUBIN, TOTAL GRADE 4 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) | CREATININE GRADE 2 | 0 Participants |
Primary
The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING )
The number of participants with clinical laboratory test abnormalities to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. Results will be categorized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life Threatening Grade 5 = Death Related to AE Baseline is defined as the last non-missing measurement prior to the first dosing date and time
Time frame: From baseline to 100 days after last dose (up to approximately 2.5 years)
Population: All treated participants with on-treatment laboratory results and CTC grade criteria available (Parts 1-9)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 4 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 3 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 3 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 2 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 3 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 3 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 2 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 2 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 2 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 3 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 1 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 1 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 1 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 3 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 3 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 4 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 2 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 1 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 1 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 1 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 2 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 5 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 4 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 6 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 2 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 5 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 4 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 5 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 4 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 2 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 4 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 3 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 3 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 3 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 3 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 2 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 3 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 4 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 3 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 2 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 2 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 1 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 3 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 2 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 1 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 4 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 1 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 1 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 1 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 2 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 4 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 6 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 4 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 4 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 3 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 3 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 5 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 5 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 2 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 1 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 1 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 1 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 2 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 1 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 1 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 3 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 2 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 8 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 5 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 1 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 2 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 2 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 1 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 1 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 4 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 2 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 3 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 1 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 1 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 2 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 2 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 6 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 9 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 1 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 2 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 3 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 2 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 1 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 1 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 1 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 1 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 1 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 4 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 2 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 3 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 2 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 2 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 3 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 2 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 1 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 4 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 2 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 1 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 2 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 2 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 1 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 2 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 2 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 2 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 2 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 4 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 2 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 1 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 1 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 1 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 4 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 1 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 1 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 1 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 1 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 1 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 1 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 1 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 1 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 3 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 3 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 2 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 1 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 2 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 1 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 2 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 4 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 2 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 1 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 2 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 5 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 2 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 2 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 1 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 1 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 2 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 2 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 1 | 1 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 2 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | GLUCOSE, FASTING SERUM GRADE 1 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 4 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 3 | 1 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 2 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 1 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 1 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 1 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | CALCIUM, TOTAL GRADE 2 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 1 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | SODIUM, SERUM GRADE 2 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 4 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | LIPASE, TOTAL GRADE 3 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | POTASSIUM, SERUM GRADE 2 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 4 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | ALBUMIN GRADE 2 | 1 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | AMYLASE, TOTAL GRADE 1 | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) | MAGNESIUM, SERUM GRADE 1 | 0 Participants |
Secondary
AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC)
The ratio of an exposure measure at steady state to that after the first dose was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
Time frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose)
Population: Pharmacokinetic participants: All participants with available serum time-concentration data from subjects who received any BMS-986178 or Nivolumab or Ipilimumab. (Parts 1-9)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Escalation Part 1: BMS 160 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC) | CYCLE 9 DAY 1 | 2.21 H*NG/ML | — |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC) | CYCLE 9 DAY 1 | 1.85 H*NG/ML | Geometric Coefficient of Variation 24 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC) | CYCLE 9 DAY 1 | 0.748 H*NG/ML | Geometric Coefficient of Variation 141 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC) | CYCLE 9 DAY 1 | 2.78 H*NG/ML | Geometric Coefficient of Variation 34 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC) | CYCLE 9 DAY 1 | 4.40 H*NG/ML | Geometric Coefficient of Variation 87 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC) | CYCLE 4 DAY 1 | 1.28 H*NG/ML | Geometric Coefficient of Variation 7 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC) | CYCLE 4 DAY 1 | 1.56 H*NG/ML | Geometric Coefficient of Variation 19 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC) | CYCLE 4 DAY 1 | 1.77 H*NG/ML | Geometric Coefficient of Variation 27 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC) | CYCLE 9 DAY 1 | 2.32 H*NG/ML | Geometric Coefficient of Variation 9 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC) | CYCLE 5 DAY 1 | 1.21 H*NG/ML | Geometric Coefficient of Variation 34 |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC) | CYCLE 4 DAY 1 | 0.000 H*NG/ML | — |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC) | CYCLE 4 DAY 1 | 1.37 H*NG/ML | Geometric Coefficient of Variation 12 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC) | CYCLE 4 DAY 1 | 2.13 H*NG/ML | Geometric Coefficient of Variation 116 |
Secondary
AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax)
The ratio of an exposure measure at steady state to that after the first dose was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
Time frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose)
Population: Pharmacokinetic participants: All participants with available serum time-concentration data from subjects who received any BMS-986178 or Nivolumab or Ipilimumab. (Parts 1-9)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Escalation Part 1: BMS 80 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 9 DAY 1 | 1.45 NG/ML | — |
| Escalation Part 1: BMS 160 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 9 DAY 1 | 1.89 NG/ML | — |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 9 DAY 1 | 1.40 NG/ML | Geometric Coefficient of Variation 22 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 9 DAY 1 | 1.29 NG/ML | Geometric Coefficient of Variation 66 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 9 DAY 1 | 1.83 NG/ML | Geometric Coefficient of Variation 14 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 9 DAY 1 | 2.56 NG/ML | Geometric Coefficient of Variation 29 |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 4 DAY 1 | 0.793 NG/ML | — |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 4 DAY 1 | 1.05 NG/ML | Geometric Coefficient of Variation 21 |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 4 DAY 1 | 1.67 NG/ML | — |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 4 DAY 1 | 1.40 NG/ML | Geometric Coefficient of Variation 18 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 4 DAY 1 | 1.52 NG/ML | Geometric Coefficient of Variation 18 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 9 DAY 1 | 1.66 NG/ML | Geometric Coefficient of Variation 32 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 5 DAY 1 | 1.02 NG/ML | Geometric Coefficient of Variation 5 |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 4 DAY 1 | 1.32 NG/ML | — |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 4 DAY 1 | 1.03 NG/ML | Geometric Coefficient of Variation 15 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) | CYCLE 4 DAY 1 | 1.21 NG/ML | Geometric Coefficient of Variation 43 |
Secondary
AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau)
The ratio of an exposure measure at steady state to that after the first dose was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
Time frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose)
Population: Pharmacokinetic participants: All participants with available serum time-concentration data from subjects who received any BMS-986178 or Nivolumab or Ipilimumab. (Parts 1-9)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Escalation Part 1: BMS 160 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau) | CYCLE 9 DAY 1 | 2.33 NG/ML | — |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau) | CYCLE 9 DAY 1 | 2.40 NG/ML | Geometric Coefficient of Variation 36 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau) | CYCLE 9 DAY 1 | 1.22 NG/ML | Geometric Coefficient of Variation 141 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau) | CYCLE 9 DAY 1 | 2.61 NG/ML | Geometric Coefficient of Variation 11 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau) | CYCLE 9 DAY 1 | 7.55 NG/ML | Geometric Coefficient of Variation 87 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau) | CYCLE 4 DAY 1 | 1.90 NG/ML | Geometric Coefficient of Variation 73 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau) | CYCLE 4 DAY 1 | 1.22 NG/ML | Geometric Coefficient of Variation 16 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau) | CYCLE 4 DAY 1 | 1.89 NG/ML | Geometric Coefficient of Variation 29 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau) | CYCLE 9 DAY 1 | 3.49 NG/ML | Geometric Coefficient of Variation 11 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau) | CYCLE 5 DAY 1 | 1.05 NG/ML | Geometric Coefficient of Variation 48 |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau) | CYCLE 4 DAY 1 | 0.000 NG/ML | — |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau) | CYCLE 4 DAY 1 | 2.47 NG/ML | Geometric Coefficient of Variation 57 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau) | CYCLE 4 DAY 1 | 2.72 NG/ML | Geometric Coefficient of Variation 116 |
Secondary
AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t
The area under the serum concentration-time curve from time 0 to time t was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
Time frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose)
Population: Pharmacokinetic participants: All participants with available serum time-concentration data from subjects who received any BMS-986178 or Nivolumab or Ipilimumab. (Parts 1-9)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 577541 H*NG/ML | Geometric Coefficient of Variation 31 |
| Escalation Part 1: BMS 40 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 1678196 H*NG/ML | Geometric Coefficient of Variation 23 |
| Escalation Part 1: BMS 80 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 1825502 H*NG/ML | Geometric Coefficient of Variation 61 |
| Escalation Part 1: BMS 80 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 9 DAY 1 | 3952990 H*NG/ML | — |
| Escalation Part 1: BMS 160 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 9 DAY 1 | 13024914 H*NG/ML | — |
| Escalation Part 1: BMS 160 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 5024906 H*NG/ML | Geometric Coefficient of Variation 32 |
| Escalation Part 1: BMS 320 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 9981469 H*NG/ML | Geometric Coefficient of Variation 9 |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 609426 H*NG/ML | Geometric Coefficient of Variation 62 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 9 DAY 1 | 2971409 H*NG/ML | Geometric Coefficient of Variation 53 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 1495494 H*NG/ML | Geometric Coefficient of Variation 27 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 9 DAY 1 | 1247687 H*NG/ML | Geometric Coefficient of Variation 118 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 2324225 H*NG/ML | Geometric Coefficient of Variation 24 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 5458640 H*NG/ML | Geometric Coefficient of Variation 47 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 9 DAY 1 | 16483279 H*NG/ML | Geometric Coefficient of Variation 37 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 9 DAY 1 | 28499982 H*NG/ML | Geometric Coefficient of Variation 78 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 8694104 H*NG/ML | Geometric Coefficient of Variation 46 |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 4 DAY 1 | 773957 H*NG/ML | — |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 1047354 H*NG/ML | Geometric Coefficient of Variation 49 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 4 DAY 1 | 2210404 H*NG/ML | Geometric Coefficient of Variation 21 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 1197507 H*NG/ML | Geometric Coefficient of Variation 43 |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 4 DAY 1 | 2400433 H*NG/ML | — |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 2774058 H*NG/ML | Geometric Coefficient of Variation 56 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 7257441 H*NG/ML | Geometric Coefficient of Variation 34 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 4 DAY 1 | 10729551 H*NG/ML | Geometric Coefficient of Variation 38 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 10580541 H*NG/ML | Geometric Coefficient of Variation 41 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 4 DAY 1 | 23851864 H*NG/ML | Geometric Coefficient of Variation 14 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 9 DAY 1 | 4537054 H*NG/ML | Geometric Coefficient of Variation 42 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 2351794 H*NG/ML | Geometric Coefficient of Variation 29 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 5 DAY 1 | 2520673 H*NG/ML | Geometric Coefficient of Variation 50 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 2000522 H*NG/ML | Geometric Coefficient of Variation 43 |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 4 DAY 1 | 2699238 H*NG/ML | — |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 3216650 H*NG/ML | Geometric Coefficient of Variation 21 |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 1251698 H*NG/ML | Geometric Coefficient of Variation 49 |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 4 DAY 1 | 1837861 H*NG/ML | Geometric Coefficient of Variation 10 |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 1653102 H*NG/ML | Geometric Coefficient of Variation 22 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 864500 H*NG/ML | Geometric Coefficient of Variation 57 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 4 DAY 1 | 504998 H*NG/ML | Geometric Coefficient of Variation 91 |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 390424 H*NG/ML | — |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t | CYCLE 1 DAY 1 | 2399055 H*NG/ML | — |
Secondary
AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval
The area under the serum concentration-time curve in 1 dosing interval was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
Time frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose)
Population: Pharmacokinetic participants: All participants with available serum time-concentration data from subjects who received any BMS-986178 or Nivolumab or Ipilimumab. (Parts 1-9)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 577541 H*NG/ML | Geometric Coefficient of Variation 31 |
| Escalation Part 1: BMS 40 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 1599886 H*NG/ML | Geometric Coefficient of Variation 29 |
| Escalation Part 1: BMS 80 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 9 DAY 1 | 3952990 H*NG/ML | — |
| Escalation Part 1: BMS 80 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 3142196 H*NG/ML | Geometric Coefficient of Variation 21 |
| Escalation Part 1: BMS 160 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 9 DAY 1 | 13024914 H*NG/ML | — |
| Escalation Part 1: BMS 160 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 5854143 H*NG/ML | Geometric Coefficient of Variation 19 |
| Escalation Part 1: BMS 320 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 9981469 H*NG/ML | Geometric Coefficient of Variation 9 |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 663257 H*NG/ML | Geometric Coefficient of Variation 60 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 9 DAY 1 | 3345948 H*NG/ML | Geometric Coefficient of Variation 40 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 1515139 H*NG/ML | Geometric Coefficient of Variation 24 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 9 DAY 1 | 3307867 H*NG/ML | Geometric Coefficient of Variation 83 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 2551115 H*NG/ML | Geometric Coefficient of Variation 24 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 9 DAY 1 | 16483279 H*NG/ML | Geometric Coefficient of Variation 37 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 5458640 H*NG/ML | Geometric Coefficient of Variation 47 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 11483961 H*NG/ML | Geometric Coefficient of Variation 26 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 9 DAY 1 | 50254284 H*NG/ML | Geometric Coefficient of Variation 42 |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 1383126 H*NG/ML | Geometric Coefficient of Variation 28 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 1521223 H*NG/ML | Geometric Coefficient of Variation 31 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 4 DAY 1 | 2210404 H*NG/ML | Geometric Coefficient of Variation 21 |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 3133192 H*NG/ML | Geometric Coefficient of Variation 49 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 7464248 H*NG/ML | Geometric Coefficient of Variation 32 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 4 DAY 1 | 12666237 H*NG/ML | Geometric Coefficient of Variation 39 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 11966698 H*NG/ML | Geometric Coefficient of Variation 34 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 4 DAY 1 | 27936423 H*NG/ML | Geometric Coefficient of Variation 8 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 9 DAY 1 | 6176469 H*NG/ML | Geometric Coefficient of Variation 17 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 2602049 H*NG/ML | Geometric Coefficient of Variation 23 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 2734577 H*NG/ML | Geometric Coefficient of Variation 31 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 5 DAY 1 | 3335668 H*NG/ML | Geometric Coefficient of Variation 56 |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 3500606 H*NG/ML | Geometric Coefficient of Variation 28 |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 4 DAY 1 | 1837861 H*NG/ML | Geometric Coefficient of Variation 10 |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 1568004 H*NG/ML | Geometric Coefficient of Variation 33 |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 1705864 H*NG/ML | Geometric Coefficient of Variation 10 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 1410042 H*NG/ML | Geometric Coefficient of Variation 23 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 4 DAY 1 | 3590883 H*NG/ML | Geometric Coefficient of Variation 12 |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 447709 H*NG/ML | — |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval | CYCLE 1 DAY 1 | 2812249 H*NG/ML | — |
Secondary
CLT: Total Body Clearance
The total body clearance was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
Time frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose)
Population: Pharmacokinetic participants: All participants with available serum time-concentration data from subjects who received any BMS-986178 or Nivolumab or Ipilimumab. (Parts 1-9)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Escalation Part 1: BMS 80 mg Q2W | CLT: Total Body Clearance | CYCLE 9 DAY 1 | 0.020 L/H | — |
| Escalation Part 1: BMS 160 mg Q2W | CLT: Total Body Clearance | CYCLE 9 DAY 1 | 0.012 L/H | — |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | CLT: Total Body Clearance | CYCLE 9 DAY 1 | 0.012 L/H | Geometric Coefficient of Variation 38 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | CLT: Total Body Clearance | CYCLE 9 DAY 1 | 0.024 L/H | Geometric Coefficient of Variation 83 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | CLT: Total Body Clearance | CYCLE 9 DAY 1 | 0.010 L/H | Geometric Coefficient of Variation 37 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | CLT: Total Body Clearance | CYCLE 9 DAY 1 | 0.006 L/H | Geometric Coefficient of Variation 42 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | CLT: Total Body Clearance | CYCLE 4 DAY 1 | 0.018 L/H | Geometric Coefficient of Variation 24 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | CLT: Total Body Clearance | CYCLE 4 DAY 1 | 0.013 L/H | Geometric Coefficient of Variation 44 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | CLT: Total Body Clearance | CYCLE 4 DAY 1 | 0.011 L/H | Geometric Coefficient of Variation 8 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | CLT: Total Body Clearance | CYCLE 9 DAY 1 | 0.013 L/H | Geometric Coefficient of Variation 19 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | CLT: Total Body Clearance | CYCLE 5 DAY 1 | 0.024 L/H | Geometric Coefficient of Variation 56 |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | CLT: Total Body Clearance | CYCLE 4 DAY 1 | 0.022 L/H | Geometric Coefficient of Variation 10 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | CLT: Total Body Clearance | CYCLE 4 DAY 1 | 0.011 L/H | Geometric Coefficient of Variation 13 |
Secondary
Cmax: Maximum Observed Serum Concentration
The maximum observed serum concentration was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
Time frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose)
Population: Pharmacokinetic participants: All participants with available serum time-concentration data from subjects who received any BMS-986178 or Nivolumab or Ipilimumab. (Parts 1-9)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 4964 NG/ML | Geometric Coefficient of Variation 11 |
| Escalation Part 1: BMS 40 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 11245 NG/ML | Geometric Coefficient of Variation 34 |
| Escalation Part 1: BMS 80 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 19254 NG/ML | Geometric Coefficient of Variation 18 |
| Escalation Part 1: BMS 80 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 9 DAY 1 | 23200 NG/ML | — |
| Escalation Part 1: BMS 160 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 9 DAY 1 | 61500 NG/ML | — |
| Escalation Part 1: BMS 160 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 36143 NG/ML | Geometric Coefficient of Variation 14 |
| Escalation Part 1: BMS 320 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 68774 NG/ML | Geometric Coefficient of Variation 20 |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 9424 NG/ML | Geometric Coefficient of Variation 133 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 9 DAY 1 | 17392 NG/ML | Geometric Coefficient of Variation 19 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 11699 NG/ML | Geometric Coefficient of Variation 13 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 9 DAY 1 | 23097 NG/ML | Geometric Coefficient of Variation 66 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 19547 NG/ML | Geometric Coefficient of Variation 39 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 39182 NG/ML | Geometric Coefficient of Variation 37 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 9 DAY 1 | 72991 NG/ML | Geometric Coefficient of Variation 12 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 9 DAY 1 | 207853 NG/ML | Geometric Coefficient of Variation 33 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 76445 NG/ML | Geometric Coefficient of Variation 22 |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | Cmax: Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 8960 NG/ML | — |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 7860 NG/ML | Geometric Coefficient of Variation 35 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | Cmax: Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 10273 NG/ML | Geometric Coefficient of Variation 12 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 9345 NG/ML | Geometric Coefficient of Variation 20 |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | Cmax: Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 20900 NG/ML | — |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 17979 NG/ML | Geometric Coefficient of Variation 31 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 55790 NG/ML | Geometric Coefficient of Variation 107 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | Cmax: Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 69922 NG/ML | Geometric Coefficient of Variation 36 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 65472 NG/ML | Geometric Coefficient of Variation 27 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Cmax: Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 117839 NG/ML | Geometric Coefficient of Variation 15 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Cmax: Maximum Observed Serum Concentration | CYCLE 9 DAY 1 | 30922 NG/ML | Geometric Coefficient of Variation 30 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 17586 NG/ML | Geometric Coefficient of Variation 25 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Cmax: Maximum Observed Serum Concentration | CYCLE 5 DAY 1 | 16912 NG/ML | Geometric Coefficient of Variation 36 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 19012 NG/ML | Geometric Coefficient of Variation 22 |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | Cmax: Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 31800 NG/ML | — |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 21399 NG/ML | Geometric Coefficient of Variation 12 |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 11139 NG/ML | Geometric Coefficient of Variation 19 |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Cmax: Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 11261 NG/ML | Geometric Coefficient of Variation 21 |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 14267 NG/ML | Geometric Coefficient of Variation 37 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 15424 NG/ML | Geometric Coefficient of Variation 173 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Cmax: Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 14143 NG/ML | Geometric Coefficient of Variation 47 |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 3270 NG/ML | — |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | Cmax: Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 11300 NG/ML | — |
Secondary
Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau)
The average concentration over a dosing interval (AUC(TAU)/tau) was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
Time frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose)
Population: Pharmacokinetic participants: All participants with available serum time-concentration data from subjects who received any BMS-986178 or Nivolumab or Ipilimumab. (Parts 1-9)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Escalation Part 1: BMS 80 mg Q2W | Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) | CYCLE 9 DAY 1 | 11826 NG/ML | — |
| Escalation Part 1: BMS 160 mg Q2W | Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) | CYCLE 9 DAY 1 | 45155 NG/ML | — |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) | CYCLE 9 DAY 1 | 9746 NG/ML | Geometric Coefficient of Variation 42 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) | CYCLE 9 DAY 1 | 9903 NG/ML | Geometric Coefficient of Variation 83 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) | CYCLE 9 DAY 1 | 45878 NG/ML | Geometric Coefficient of Variation 27 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) | CYCLE 9 DAY 1 | 148579 NG/ML | Geometric Coefficient of Variation 42 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) | CYCLE 4 DAY 1 | 4379 NG/ML | Geometric Coefficient of Variation 21 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) | CYCLE 4 DAY 1 | 25131 NG/ML | Geometric Coefficient of Variation 39 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) | CYCLE 4 DAY 1 | 55386 NG/ML | Geometric Coefficient of Variation 8 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) | CYCLE 9 DAY 1 | 19538 NG/ML | Geometric Coefficient of Variation 19 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) | CYCLE 5 DAY 1 | 4964 NG/ML | Geometric Coefficient of Variation 56 |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) | CYCLE 4 DAY 1 | 3715 NG/ML | Geometric Coefficient of Variation 10 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) | CYCLE 4 DAY 1 | 10739 NG/ML | Geometric Coefficient of Variation 12 |
Secondary
Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected
The observed serum concentration at the end of a dosing interval when intensive samples are collected was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
Time frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose)
Population: Pharmacokinetic participants: All participants with available serum time-concentration data from subjects who received any BMS-986178 or Nivolumab or Ipilimumab. (Parts 1-9)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 657 NG/ML | Geometric Coefficient of Variation 62 |
| Escalation Part 1: BMS 40 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 2577 NG/ML | Geometric Coefficient of Variation 30 |
| Escalation Part 1: BMS 80 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 9 DAY 1 | 6470 NG/ML | — |
| Escalation Part 1: BMS 80 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 5354 NG/ML | Geometric Coefficient of Variation 31 |
| Escalation Part 1: BMS 160 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 9 DAY 1 | 33600 NG/ML | — |
| Escalation Part 1: BMS 160 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 10852 NG/ML | Geometric Coefficient of Variation 44 |
| Escalation Part 1: BMS 320 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 16514 NG/ML | Geometric Coefficient of Variation 4 |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 756 NG/ML | Geometric Coefficient of Variation 108 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 9 DAY 1 | 5510 NG/ML | Geometric Coefficient of Variation 68 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 1904 NG/ML | Geometric Coefficient of Variation 37 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 9 DAY 1 | 5686 NG/ML | Geometric Coefficient of Variation 78 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 3598 NG/ML | Geometric Coefficient of Variation 37 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 9 DAY 1 | 34303 NG/ML | Geometric Coefficient of Variation 25 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 10413 NG/ML | Geometric Coefficient of Variation 51 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 18596 NG/ML | Geometric Coefficient of Variation 41 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 9 DAY 1 | 131520 NG/ML | Geometric Coefficient of Variation 70 |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 885 NG/ML | Geometric Coefficient of Variation 56 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 604 NG/ML | Geometric Coefficient of Variation 67 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 4 DAY 1 | 2527 NG/ML | Geometric Coefficient of Variation 68 |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 2335 NG/ML | Geometric Coefficient of Variation 87 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 3059 NG/ML | Geometric Coefficient of Variation 93 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 4 DAY 1 | 7729 NG/ML | Geometric Coefficient of Variation 49 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 7739 NG/ML | Geometric Coefficient of Variation 72 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 4 DAY 1 | 32982 NG/ML | Geometric Coefficient of Variation 33 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 9 DAY 1 | 13400 NG/ML | Geometric Coefficient of Variation 26 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 3928 NG/ML | Geometric Coefficient of Variation 33 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 544 NG/ML | Geometric Coefficient of Variation 76 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 5 DAY 1 | 1412 NG/ML | Geometric Coefficient of Variation 78 |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 1725 NG/ML | Geometric Coefficient of Variation 76 |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 4 DAY 1 | 1262 NG/ML | Geometric Coefficient of Variation 10 |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 790 NG/ML | Geometric Coefficient of Variation 88 |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 1535 NG/ML | Geometric Coefficient of Variation 35 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 1533 NG/ML | Geometric Coefficient of Variation 54 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 4 DAY 1 | 6906 NG/ML | Geometric Coefficient of Variation 20 |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 0.004 NG/ML | — |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected | CYCLE 1 DAY 1 | 42.9 NG/ML | — |
Secondary
Ctrough: Trough Observed Plasma Concentration
Trough observed plasma concentration (this includes predose concentrations and Ctau concentrations) was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
Time frame: Cycle 1-17 timepoints can include (Pre-dose, 336, 504, 672 hours post dose)
Population: Pharmacokinetic participants: All participants with available serum time-concentration data from subjects who received any BMS-986178 or Nivolumab or Ipilimumab. (Parts 1-9)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 3420 ng/mL | — |
| Escalation Part 1: BMS 20 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 1290 ng/mL | Geometric Coefficient of Variation 43.3 |
| Escalation Part 1: BMS 20 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 336 h | 657 ng/mL | Geometric Coefficient of Variation 62.2 |
| Escalation Part 1: BMS 40 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 4593 ng/mL | Geometric Coefficient of Variation 24 |
| Escalation Part 1: BMS 40 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 4244 ng/mL | Geometric Coefficient of Variation 36.2 |
| Escalation Part 1: BMS 40 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 5 DAY 1 0 h | 6600 ng/mL | — |
| Escalation Part 1: BMS 40 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 336 h | 2372 ng/mL | Geometric Coefficient of Variation 38.9 |
| Escalation Part 1: BMS 40 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 7 DAY 1 0 h | 5390 ng/mL | — |
| Escalation Part 1: BMS 80 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 9 DAY 1 0 h | 6300 ng/mL | — |
| Escalation Part 1: BMS 80 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 7 DAY 1 0 h | 10217 ng/mL | Geometric Coefficient of Variation 45.8 |
| Escalation Part 1: BMS 80 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 10 DAY 1 336 h | 6470 ng/mL | — |
| Escalation Part 1: BMS 80 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 5903 ng/mL | Geometric Coefficient of Variation 45.5 |
| Escalation Part 1: BMS 80 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 7169 ng/mL | Geometric Coefficient of Variation 37.3 |
| Escalation Part 1: BMS 80 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 336 h | 5354 ng/mL | Geometric Coefficient of Variation 31 |
| Escalation Part 1: BMS 80 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 5 DAY 1 0 h | 13491 ng/mL | Geometric Coefficient of Variation 36 |
| Escalation Part 1: BMS 160 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 16974 ng/mL | Geometric Coefficient of Variation 28.9 |
| Escalation Part 1: BMS 160 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 336 h | 10852 ng/mL | Geometric Coefficient of Variation 44.3 |
| Escalation Part 1: BMS 160 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 20703 ng/mL | Geometric Coefficient of Variation 32.1 |
| Escalation Part 1: BMS 160 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 5 DAY 1 0 h | 13300 ng/mL | — |
| Escalation Part 1: BMS 160 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 7 DAY 1 0 h | 22073 ng/mL | Geometric Coefficient of Variation 60.3 |
| Escalation Part 1: BMS 160 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 9 DAY 1 0 h | 31300 ng/mL | — |
| Escalation Part 1: BMS 160 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 10 DAY 1 336 h | 33600 ng/mL | — |
| Escalation Part 1: BMS 320 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 336 h | 16514 ng/mL | Geometric Coefficient of Variation 4.14 |
| Escalation Part 1: BMS 320 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 5 DAY 1 0 h | 35200 ng/mL | — |
| Escalation Part 1: BMS 320 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 21571 ng/mL | Geometric Coefficient of Variation 15.9 |
| Escalation Part 1: BMS 320 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 26090 ng/mL | Geometric Coefficient of Variation 13 |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 336 h | 561 ng/mL | Geometric Coefficient of Variation 119 |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 10 DAY 1 336 h | 1190 ng/mL | — |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 614 ng/mL | Geometric Coefficient of Variation 122 |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 7 DAY 1 0 h | 946 ng/mL | — |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 5 DAY 1 0 h | 386 ng/mL | Geometric Coefficient of Variation 84.8 |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 358 ng/mL | Geometric Coefficient of Variation 95.8 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 1825 ng/mL | Geometric Coefficient of Variation 70.1 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 9 DAY 1 0 h | 6397 ng/mL | Geometric Coefficient of Variation 50.5 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 5 DAY 1 0 h | 1301 ng/mL | Geometric Coefficient of Variation 100 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 2095 ng/mL | Geometric Coefficient of Variation 96.5 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 336 h | 1995 ng/mL | Geometric Coefficient of Variation 35.1 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 10 DAY 1 336 h | 8264 ng/mL | Geometric Coefficient of Variation 44 |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 7 DAY 1 0 h | 4777 ng/mL | Geometric Coefficient of Variation 75.6 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 9 DAY 1 0 h | 13536 ng/mL | Geometric Coefficient of Variation 105 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 5 DAY 1 0 h | 7468 ng/mL | Geometric Coefficient of Variation 55.1 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 10 DAY 1 336 h | 5686 ng/mL | Geometric Coefficient of Variation 78.2 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 336 h | 4006 ng/mL | Geometric Coefficient of Variation 31 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 7 DAY 1 0 h | 12527 ng/mL | Geometric Coefficient of Variation 58.8 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 4498 ng/mL | Geometric Coefficient of Variation 45.4 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 5108 ng/mL | Geometric Coefficient of Variation 71.4 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 10 DAY 1 336 h | 28988 ng/mL | Geometric Coefficient of Variation 33.9 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 9 DAY 1 0 h | 29902 ng/mL | Geometric Coefficient of Variation 30 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 5 DAY 1 0 h | 26813 ng/mL | Geometric Coefficient of Variation 52.7 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 20800 ng/mL | Geometric Coefficient of Variation 43.7 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 7 DAY 1 0 h | 32753 ng/mL | Geometric Coefficient of Variation 53.9 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 16379 ng/mL | Geometric Coefficient of Variation 43.6 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 17 DAY 1 0 h | 48500 ng/mL | — |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 336 h | 10413 ng/mL | Geometric Coefficient of Variation 51.3 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 9 DAY 1 0 h | 106710 ng/mL | Geometric Coefficient of Variation 40.9 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 336 h | 18596 ng/mL | Geometric Coefficient of Variation 41.4 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 28282 ng/mL | Geometric Coefficient of Variation 43.2 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 47108 ng/mL | Geometric Coefficient of Variation 45.2 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 5 DAY 1 0 h | 90700 ng/mL | — |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 7 DAY 1 0 h | 76970 ng/mL | Geometric Coefficient of Variation 33 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Ctrough: Trough Observed Plasma Concentration | CYCLE 10 DAY 1 336 h | 131520 ng/mL | Geometric Coefficient of Variation 70.3 |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 504 h | 456 ng/mL | Geometric Coefficient of Variation 85.5 |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 1080 ng/mL | — |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 323 ng/mL | Geometric Coefficient of Variation 101 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 5 DAY 1 504 h | 2527 ng/mL | Geometric Coefficient of Variation 67.6 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 2049 ng/mL | Geometric Coefficient of Variation 40.1 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 1971 ng/mL | Geometric Coefficient of Variation 51.3 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 504 h | 591 ng/mL | Geometric Coefficient of Variation 76.7 |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 5140 ng/mL | — |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 504 h | 2401 ng/mL | Geometric Coefficient of Variation 86 |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 4894 ng/mL | Geometric Coefficient of Variation 60.7 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 2766 ng/mL | Geometric Coefficient of Variation 99.8 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 12649 ng/mL | Geometric Coefficient of Variation 78.3 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 504 h | 1921 ng/mL | Geometric Coefficient of Variation 103 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 32150 ng/mL | Geometric Coefficient of Variation 0.66 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 5 DAY 1 504 h | 18771 ng/mL | Geometric Coefficient of Variation 45 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 504 h | 7739 ng/mL | Geometric Coefficient of Variation 72.3 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 10 DAY 1 0 h | 29100 ng/mL | — |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 20410 ng/mL | Geometric Coefficient of Variation 42.5 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 5055 ng/mL | Geometric Coefficient of Variation 46.8 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 7252 ng/mL | Geometric Coefficient of Variation 43.4 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 10 DAY 1 336 h | 13400 ng/mL | Geometric Coefficient of Variation 26.3 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 5 DAY 1 0 h | 9811 ng/mL | Geometric Coefficient of Variation 37.3 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 7 DAY 1 0 h | 11471 ng/mL | Geometric Coefficient of Variation 38.5 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 9 DAY 1 0 h | 12905 ng/mL | Geometric Coefficient of Variation 42.4 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 336 h | 4070 ng/mL | Geometric Coefficient of Variation 30.7 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 17 DAY 1 0 h | 16600 ng/mL | — |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 672 h | 676 ng/mL | Geometric Coefficient of Variation 105 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 1466 ng/mL | Geometric Coefficient of Variation 72.4 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 1480 ng/mL | Geometric Coefficient of Variation 81.5 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Ctrough: Trough Observed Plasma Concentration | CYCLE 6 DAY 1 672 h | 62.5 ng/mL | — |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Ctrough: Trough Observed Plasma Concentration | CYCLE 5 DAY 1 0 h | 1671 ng/mL | Geometric Coefficient of Variation 63.5 |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 62.5 ng/mL | — |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 504 h | 2166 ng/mL | Geometric Coefficient of Variation 33.7 |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 5 DAY 1 504 h | 1262 ng/mL | Geometric Coefficient of Variation 10.2 |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 689 ng/mL | Geometric Coefficient of Variation 123 |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 9 DAY 1 0 h | 579 ng/mL | — |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 754 ng/mL | Geometric Coefficient of Variation 48.1 |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 504 h | 745 ng/mL | Geometric Coefficient of Variation 90.9 |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 504 h | 1030 ng/mL | — |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 1 DAY 15 336 h | 1535 ng/mL | Geometric Coefficient of Variation 34.9 |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 1 DAY 29 0 h | 1354 ng/mL | Geometric Coefficient of Variation 65 |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 0 h | 1391 ng/mL | Geometric Coefficient of Variation 63.3 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 1 DAY 15 336 h | 1912 ng/mL | Geometric Coefficient of Variation 45.2 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 3 DAY 1 0 h | 2469 ng/mL | Geometric Coefficient of Variation 64.6 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 15 336 h | 2130 ng/mL | Geometric Coefficient of Variation 69.4 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 6 DAY 1 0 h | 604 ng/mL | Geometric Coefficient of Variation 138 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 1 0 h | 5461 ng/mL | Geometric Coefficient of Variation 26.4 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 4 DAY 29 0 | 1856 ng/mL | Geometric Coefficient of Variation 75.1 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 2 DAY 1 0 h | 1107 ng/mL | Geometric Coefficient of Variation 84.5 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Ctrough: Trough Observed Plasma Concentration | CYCLE 1 DAY 29 0 h | 1108 ng/mL | Geometric Coefficient of Variation 72.9 |
Secondary
Duration of Response (DOR)
The time between the date of first response and the subsequent date of disease progression or death (death after re-treatment will not be considered), whichever occurs first in participants with a best overall response (BOR) of complete response (CR) or partial response (PR). Best overall response (BOR) is assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions. Baseline is defined as the last non-missing measurement prior to the first dosing date and time. Due to high percentage of censored response, median estimate may be misleading
Time frame: From baseline up to approximately 2.5 years
Population: The number of responders within each tumor type was not sufficient for analysis. (Parts 1-8)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Duration of Response (DOR) | NA Weeks |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Duration of Response (DOR) | 17.14 Weeks |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Duration of Response (DOR) | NA Weeks |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Duration of Response (DOR) | NA Weeks |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Duration of Response (DOR) | NA Weeks |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Duration of Response (DOR) | 64.14 Weeks |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Duration of Response (DOR) | NA Weeks |
Secondary
Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178
The number of participants with positive anti-drug antibodies (ADA) is assessed to characterize the immunogenicity of BMS-986178 administered alone or in combination with nivolumab and/or ipilimumab. ADA Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment.
Time frame: Cycle 1-6 timepoints can include (Pre-dose, 696 hours post dose)
Population: All BMS 986178 Treated Participants with Baseline and at Least One Post-baseline ADA Assessment (Parts 1-9)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 3 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 1 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 3 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 1 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 0 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 1 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 3 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 1 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 4 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 2 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 1 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 | 0 Participants |
Secondary
Frequency of Positive Anti-Drug Antibodies (ADA) to Ipilimumab.
The number of participants with positive anti-drug antibodies (ADA) is assessed to characterize the immunogenicity of Ipilimumab administered with BMS-986178 ADA Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment.
Time frame: Cycle 1-6 timepoints can include (Pre-dose, 696 hours post dose)
Population: All BMS 986178 Treated Participants with Baseline and at Least One Post-baseline ADA Assessment (Parts 1-9)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Ipilimumab. | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Ipilimumab. | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Ipilimumab. | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Ipilimumab. | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Ipilimumab. | 1 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Ipilimumab. | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Ipilimumab. | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Ipilimumab. | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Ipilimumab. | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Ipilimumab. | 0 Participants |
Secondary
Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab
The number of participants with positive anti-drug antibodies (ADA) is assessed to characterize the immunogenicity of Nivolumab administered with BMS-986178 ADA Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment.
Time frame: Cycle 1-6 timepoints can include (Pre-dose, 336, 696 hours post dose)
Population: All BMS 986178 Treated Participants with Baseline and at Least One Post-baseline ADA Assessment (Parts 1-9)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab | 1 Participants |
| Escalation Part 1: BMS 80 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab | 3 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab | 0 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab | 0 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab | 0 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab | 1 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab | 1 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab | 1 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab | 0 Participants |
Secondary
Objective Response Rate (ORR)
The total number of participants whose best overall response (BOR) is either a complete response (CR) or partial response (PR) based on assessment of tumor response using RECIST v1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions. Overall Response (OR) = CR + PR Baseline is defined as the last non-missing measurement prior to the first dosing date and time.
Time frame: From baseline up to approximately 2.5 years
Population: Response Evaluable Participants (Parts 1-9)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | Objective Response Rate (ORR) | 0 Participants |
| Escalation Part 1: BMS 40 mg Q2W | Objective Response Rate (ORR) | 0 Participants |
| Escalation Part 1: BMS 80 mg Q2W | Objective Response Rate (ORR) | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | Objective Response Rate (ORR) | 0 Participants |
| Escalation Part 1: BMS 320 mg Q2W | Objective Response Rate (ORR) | 0 Participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | Objective Response Rate (ORR) | 0 Participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Objective Response Rate (ORR) | 2 Participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Objective Response Rate (ORR) | 1 Participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Objective Response Rate (ORR) | 1 Participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Objective Response Rate (ORR) | 1 Participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | Objective Response Rate (ORR) | 0 Participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | Objective Response Rate (ORR) | 0 Participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | Objective Response Rate (ORR) | 0 Participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | Objective Response Rate (ORR) | 0 Participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Objective Response Rate (ORR) | 0 Participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Objective Response Rate (ORR) | 1 Participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Objective Response Rate (ORR) | 0 Participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | Objective Response Rate (ORR) | 0 Participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Objective Response Rate (ORR) | 1 Participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Objective Response Rate (ORR) | 0 Participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Objective Response Rate (ORR) | 0 Participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Objective Response Rate (ORR) | 2 Participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | Objective Response Rate (ORR) | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | Objective Response Rate (ORR) | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | Objective Response Rate (ORR) | 0 Participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | Objective Response Rate (ORR) | 0 Participants |
| Exploration Part 9 Cohort 1: BMS 40 mg Q4W + Nivo 480 mg Q4W + DRibble Vaccine | Objective Response Rate (ORR) | NA Participants |
Secondary
Progression Free Survival (PFS) Rate at 24 Weeks
The percentage of treated participants remaining progression free and surviving at 24 weeks since the first dosing date.
Time frame: 24 weeks after first dose
Population: All treated Participants (Parts 1-8)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | Progression Free Survival (PFS) Rate at 24 Weeks | 0.0 Percentage of participants |
| Escalation Part 1: BMS 40 mg Q2W | Progression Free Survival (PFS) Rate at 24 Weeks | 0.0 Percentage of participants |
| Escalation Part 1: BMS 80 mg Q2W | Progression Free Survival (PFS) Rate at 24 Weeks | 0.0 Percentage of participants |
| Escalation Part 1: BMS 160 mg Q2W | Progression Free Survival (PFS) Rate at 24 Weeks | 25.0 Percentage of participants |
| Escalation Part 1: BMS 320 mg Q2W | Progression Free Survival (PFS) Rate at 24 Weeks | 25.0 Percentage of participants |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | Progression Free Survival (PFS) Rate at 24 Weeks | 17.9 Percentage of participants |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Progression Free Survival (PFS) Rate at 24 Weeks | 42.9 Percentage of participants |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Progression Free Survival (PFS) Rate at 24 Weeks | 16.7 Percentage of participants |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Progression Free Survival (PFS) Rate at 24 Weeks | 28.6 Percentage of participants |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Progression Free Survival (PFS) Rate at 24 Weeks | 37.5 Percentage of participants |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | Progression Free Survival (PFS) Rate at 24 Weeks | 0.0 Percentage of participants |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | Progression Free Survival (PFS) Rate at 24 Weeks | 11.1 Percentage of participants |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | Progression Free Survival (PFS) Rate at 24 Weeks | 0.0 Percentage of participants |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | Progression Free Survival (PFS) Rate at 24 Weeks | 0.0 Percentage of participants |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Progression Free Survival (PFS) Rate at 24 Weeks | 40.0 Percentage of participants |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Progression Free Survival (PFS) Rate at 24 Weeks | 22.2 Percentage of participants |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Progression Free Survival (PFS) Rate at 24 Weeks | 9.2 Percentage of participants |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | Progression Free Survival (PFS) Rate at 24 Weeks | 0.0 Percentage of participants |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Progression Free Survival (PFS) Rate at 24 Weeks | 28.6 Percentage of participants |
| Expansion Part 6B: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Progression Free Survival (PFS) Rate at 24 Weeks | NA Percentage of participants |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Progression Free Survival (PFS) Rate at 24 Weeks | 0.0 Percentage of participants |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Progression Free Survival (PFS) Rate at 24 Weeks | 33.3 Percentage of participants |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | Progression Free Survival (PFS) Rate at 24 Weeks | 0.0 Percentage of participants |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | Progression Free Survival (PFS) Rate at 24 Weeks | 0.0 Percentage of participants |
| Schedule and Dose Exploration Part 8: Cohort 3- BMS 80 mg Q12W + Nivo 480 mg Q4W | Progression Free Survival (PFS) Rate at 24 Weeks | 0.0 Percentage of participants |
| Schedule and Dose Exploration Part 8: Cohort 4- Nivo 480 mg Q4W | Progression Free Survival (PFS) Rate at 24 Weeks | 50.0 Percentage of participants |
Secondary
T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax)
The effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab
Time frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose)
Population: Pharmacokinetic participants: All participants with available serum time-concentration data from subjects who received any BMS-986178 or Nivolumab or Ipilimumab. (Parts 1-9)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Escalation Part 1: BMS 80 mg Q2W | T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) | CYCLE 9 DAY 1 | 0.000 Hr | — |
| Escalation Part 1: BMS 160 mg Q2W | T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) | CYCLE 9 DAY 1 | 331 Hr | — |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) | CYCLE 9 DAY 1 | 315 Hr | Standard Deviation 119 |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) | CYCLE 9 DAY 1 | 0.000 Hr | Standard Deviation 0 |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) | CYCLE 9 DAY 1 | 593 Hr | Standard Deviation 308 |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) | CYCLE 9 DAY 1 | 607 Hr | Standard Deviation 527 |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) | CYCLE 4 DAY 1 | 229 Hr | Standard Deviation 40 |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) | CYCLE 4 DAY 1 | 345 Hr | Standard Deviation 111 |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) | CYCLE 4 DAY 1 | 429 Hr | Standard Deviation 182 |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) | CYCLE 9 DAY 1 | 312 Hr | Standard Deviation 180 |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) | CYCLE 5 DAY 1 | 447 Hr | — |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) | CYCLE 4 DAY 1 | 0.000 Hr | — |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) | CYCLE 4 DAY 1 | 261 Hr | Standard Deviation 58 |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) | CYCLE 4 DAY 1 | 146 Hr | Standard Deviation 200 |
Secondary
The Number of Participants Showing a Change in Soluble OX40 and Peripheral OX40 Receptor Occupancy Pharmacodynamic Biomarkers in Part 8
The Number of Participants Showing a Change in Soluble OX40 and Peripheral OX40 Receptor Occupancy Pharmacodynamic Biomarkers in Part 8. A threshold of 80% receptor occupancy following treatment was applied.
Time frame: Cycle 1-6 timepoints can include (Pre-dose, 24, 168, 336, 672, 1848 hours post dose)
Population: All treated participants with Pharmacodynamic biomarker assessments (Part 8)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants Showing a Change in Soluble OX40 and Peripheral OX40 Receptor Occupancy Pharmacodynamic Biomarkers in Part 8 | Peripheral OX40 receptor occupancy (Tregs) | 1 Participants |
| Escalation Part 1: BMS 20 mg Q2W | The Number of Participants Showing a Change in Soluble OX40 and Peripheral OX40 Receptor Occupancy Pharmacodynamic Biomarkers in Part 8 | Peripheral OX40 receptor occupancy (CD4+ T cells) | 1 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants Showing a Change in Soluble OX40 and Peripheral OX40 Receptor Occupancy Pharmacodynamic Biomarkers in Part 8 | Peripheral OX40 receptor occupancy (CD4+ T cells) | 2 Participants |
| Escalation Part 1: BMS 40 mg Q2W | The Number of Participants Showing a Change in Soluble OX40 and Peripheral OX40 Receptor Occupancy Pharmacodynamic Biomarkers in Part 8 | Peripheral OX40 receptor occupancy (Tregs) | 1 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants Showing a Change in Soluble OX40 and Peripheral OX40 Receptor Occupancy Pharmacodynamic Biomarkers in Part 8 | Peripheral OX40 receptor occupancy (Tregs) | 1 Participants |
| Escalation Part 1: BMS 80 mg Q2W | The Number of Participants Showing a Change in Soluble OX40 and Peripheral OX40 Receptor Occupancy Pharmacodynamic Biomarkers in Part 8 | Peripheral OX40 receptor occupancy (CD4+ T cells) | 1 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants Showing a Change in Soluble OX40 and Peripheral OX40 Receptor Occupancy Pharmacodynamic Biomarkers in Part 8 | Peripheral OX40 receptor occupancy (Tregs) | 0 Participants |
| Escalation Part 1: BMS 160 mg Q2W | The Number of Participants Showing a Change in Soluble OX40 and Peripheral OX40 Receptor Occupancy Pharmacodynamic Biomarkers in Part 8 | Peripheral OX40 receptor occupancy (CD4+ T cells) | 0 Participants |
| Unknown | The Number of Participants Showing a Change in Soluble OX40 and Peripheral OX40 Receptor Occupancy Pharmacodynamic Biomarkers in Part 8 | Soluble OX40 | — Participants |
Secondary
The Number of Participants With Sustained T Cell Expansion With DPV-001 in Combination With Nivolumab or Nivolumab Monotherapy in Part 9
The number of participants with Sustained T Cell Expansion with DPV-001 in Combination with Nivolumab or Nivolumab Monotherapy was assessed to show a change in pharmacodynamics biomarkers
Time frame: Cycle 1-6 timepoints can include (Pre-dose, 24, 168, 336, 672, 1848 hours post dose)
Population: All treated participants with available biomarker data (Part 9)
Secondary
Tmax: Time of Maximum Observed Serum Concentration
The time of maximum observed serum concentration was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab
Time frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose)
Population: Pharmacokinetic participants: All participants with available serum time-concentration data from subjects who received any BMS-986178 or Nivolumab or Ipilimumab. (Parts 1-9)
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Escalation Part 1: BMS 20 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 0.675 Hours |
| Escalation Part 1: BMS 40 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 0.575 Hours |
| Escalation Part 1: BMS 80 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 9 DAY 1 | 0.467 Hours |
| Escalation Part 1: BMS 80 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 4.58 Hours |
| Escalation Part 1: BMS 160 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 9 DAY 1 | 22.7 Hours |
| Escalation Part 1: BMS 160 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 2.30 Hours |
| Escalation Part 1: BMS 320 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 0.558 Hours |
| Escalation Part 2 BMS 20 mg + Nivo 240 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 0.467 Hours |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 2.34 Hours |
| Escalation Part 2: BMS 40 mg + Nivo 240 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 9 DAY 1 | 0.567 Hours |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 0.517 Hours |
| Escalation Part 2: BMS 80 mg + Nivo 240 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 9 DAY 1 | 4.47 Hours |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 0.650 Hours |
| Escalation Part 2: BMS 160 mg + Nivo 240 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 9 DAY 1 | 2.38 Hours |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 0.792 Hours |
| Escalation Part 2: BMS 320 mg + Nivo 240 mg Q2W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 9 DAY 1 | 4.05 Hours |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 0.583 Hours |
| Escalation Part 3: BMS 20 mg + Ipi 1 mg/kg Q3W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 0.667 Hours |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 4.00 Hours |
| Escalation Part 3: BMS 40 mg + Ipi 1 mg/kg Q3W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 4.00 Hours |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 0.583 Hours |
| Escalation Part 3: BMS 80 mg + Ipi 1 mg/kg Q3W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 4.00 Hours |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 2.55 Hours |
| Escalation Part 3: BMS 160 mg + Ipi 1 mg/kg Q3W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 4.00 Hours |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 4.13 Hours |
| Escalation Part 3: BMS 320 mg + Ipi 1 mg/kg Q3W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 2.58 Hours |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 9 DAY 1 | 3.94 Hours |
| Expansion Part 2C: BMS 80 mg + Nivo 240 mg Q2W (BDC) | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 4.09 Hours |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 5 DAY 1 | 0.550 Hours |
| Schedule and Dose Exploration Part 4: BMS 80 mg + Nivo 480 mg Q4W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 0.550 Hours |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 4.03 Hours |
| Schedule and Dose Exploration Part 5: BMS 80 mg + Ipi 3 mg/kg Q3W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 2.30 Hours |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 0.517 Hours |
| Safety Part 6A: BMS 40 mg + Nivo 240 mg + Ipi 1 mg/kg Q3W / BMS 40 mg + Nivo 480 mg Q4W (RCC) | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 0.583 Hours |
| Safety Cohort Part 7A: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 4.00 Hours |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 0.475 Hours |
| Expansion Part 7B: BMS 40mg Q2W + Nivo 240 mg Q2W + Ipi 1 mg/kg Q6W (NSCLC) | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 4 DAY 1 | 0.467 Hours |
| Schedule and Dose Exploration Part 8: Cohort 1- BMS 20 mg Q12W + Nivo 480 mg Q4W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 0.533 Hours |
| Schedule and Dose Exploration Part 8: Cohort 2- BMS 40 mg Q12W + Nivo 480 mg Q4W | Tmax: Time of Maximum Observed Serum Concentration | CYCLE 1 DAY 1 | 4.83 Hours |
Secondary
Tumor Pharmacodynamics of BMS-986178 in Combination With Nivolumab or Nivolumab Monotherapy in Part 8
Tumor pharmacodynamics of BMS-986178 in combination with nivolumab or nivolumab monotherapy
Time frame: Screening, cycle 1-2 timepoints can include (Pre-dose, 336, 1848 hours post dose)
Population: Tumor pharmacodynamic readouts not possible due to only 1 matched pair